Skip to main content

Table 2 Percent (%) biosimilar share of reference product sales [14],[39]

From: Potential impact of subsequent entry biologics in nephrology practice in Canada

  Percent (%) biosimilar share of reference product sales  
  Austria France Germany Italy Poland Spain Sweden UK EU total
Epoetin 50 11 65 7 62 16 63 9 18
Filgrastim 52 42 45 18 38 24 45 80 38
Somatropin 6 20 12 12 7 15 21 4 13
Infliximab Approved but not yet marketed